NCT06356883View on ClinicalTrials.gov

Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions

Glioblastoma MultiformeRelapse

Interventions

DRUG

IA Carboplatin + IA Caelyx

Intraarterial infusion of carboplatin combined with liposomal doxorubicin

DRUG

IA Carboplatin + IA Etoposide Phosphate

Intraarterial infusion of carboplatin combined with etoposide phosphate

Trial Locations (1)

J1H 5N4

RECRUITING

CHUS, Sherbrooke

All Listed Sponsors

lead

Université de Sherbrooke

OTHER

NCT06356883 - Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | Biotech Hunter | Biotech Hunter